Rationally designed inhibitors of the Musashi protein-RNA interaction by hotspot mimicry

RNA-binding proteins (RBPs) are key post-transcriptional regulators of gene expression, and thus underlie many important biological processes. Here, we developed a strategy that entails extracting a “hotspot pharmacophore” from the structure of a protein-RNA complex, to create a template for designing small-molecule inhibitors and for exploring the selectivity of the resulting inhibitors. We demonstrate this approach by designing inhibitors of Musashi proteins MSI1 and MSI2, key regulators of mRNA stability and translation that are upregulated in many cancers. We report this novel series of MSI1/MSI2 inhibitors is specific and active in biochemical, biophysical, and cellular assays. This study extends the paradigm of “hotspots” from protein-protein complexes to protein-RNA complexes, supports the “druggability” of RNA-binding protein surfaces, and represents one of the first rationally-designed inhibitors of non-enzymatic RNA-binding proteins. Owing to its simplicity and generality, we anticipate that this approach may also be used to develop inhibitors of many other RNA-binding proteins; we also consider the prospects of identifying potential off-target interactions by searching for other RBPs that recognize their cognate RNAs using similar interaction geometries. Beyond inhibitors, we also expect that compounds designed using this approach can serve as warheads for new PROTACs that selectively degrade RNA-binding proteins.

[1]  Gene W. Yeo,et al.  Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma , 2022, Nature Communications.

[2]  I. Anishchenko,et al.  Accurate prediction of nucleic acid and protein-nucleic acid complexes using RoseTTAFoldNA , 2022, bioRxiv.

[3]  S. Mehrotra,et al.  HuR as a molecular target for cancer therapeutics and immune-related disorders. , 2022, Advanced drug delivery reviews.

[4]  Zhiyu Li,et al.  A critical update on the strategies towards small molecule inhibitors targeting Serine/arginine-rich (SR) proteins and Serine/arginine-rich proteins related kinases in alternative splicing. , 2022, Bioorganic & medicinal chemistry.

[5]  Fabian M. Troschel,et al.  Knockdown of the stem cell marker Musashi-1 inhibits endometrial cancer growth and sensitizes cells to radiation , 2022, Stem cell research & therapy.

[6]  Donghyun Lim,et al.  Small-molecule modulators of protein-RNA interactions. , 2022, Current opinion in chemical biology.

[7]  Yun-di Guo,et al.  A novel SRSF3 inhibitor, SFI003, exerts anticancer activity against colorectal cancer by modulating the SRSF3/DHCR24/ROS axis , 2022, Cell death discovery.

[8]  Qiang Xu,et al.  Small molecule targeting CELF1 RNA-binding activity to control HSC activation and liver fibrosis , 2022, Nucleic acids research.

[9]  Liang Xu,et al.  The RNA-binding protein HuR in human cancer: a friend or foe? , 2022, Advanced drug delivery reviews.

[10]  X. Ke,et al.  Small Molecule Palmatine Targeting Musashi-2 in Colorectal Cancer , 2022, Frontiers in Pharmacology.

[11]  C. Leslie,et al.  TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma , 2021, Nature Communications.

[12]  Fabian M. Troschel,et al.  Dual Knockdown of Musashi RNA-Binding Proteins MSI-1 and MSI-2 Attenuates Putative Cancer Stem Cell Characteristics and Therapy Resistance in Ovarian Cancer Cells , 2021, International journal of molecular sciences.

[13]  Derek J. Essegian,et al.  Discovery of an eIF4A Inhibitor with a Novel Mechanism of Action. , 2021, Journal of medicinal chemistry.

[14]  F. Vasile,et al.  Identification of N,N-arylalkyl-picolinamide derivatives targeting the RNA-binding protein HuR, by combining biophysical fragment-screening and molecular hybridization. , 2021, Bioorganic chemistry (Print).

[15]  Fabian M. Troschel,et al.  Knockdown of the prognostic cancer stem cell marker Musashi-1 decreases radio-resistance while enhancing apoptosis in hormone receptor-positive breast cancer cells via p21WAF1/CIP1 , 2021, Journal of Cancer Research and Clinical Oncology.

[16]  T. Kohno,et al.  MUSASHI‐2 confers resistance to third‐generation EGFR‐tyrosine kinase inhibitor osimertinib in lung adenocarcinoma , 2021, Cancer science.

[17]  M. Lederer,et al.  Musashi–1—A Stemness RBP for Cancer Therapy? , 2021, Biology.

[18]  M. Edelman,et al.  Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC) , 2021, Oncogenesis.

[19]  R. J. Ross,et al.  Integrative genome-wide analysis reveals EIF3A as a key downstream regulator of translational repressor protein Musashi 2 (MSI2) , 2021, bioRxiv.

[20]  Keriann M. Backus,et al.  New approaches to target RNA binding proteins. , 2021, Current opinion in chemical biology.

[21]  O. Abdel-Wahab,et al.  Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target , 2021, Leukemia.

[22]  Yurii S. Moroz,et al.  Generating Multibillion Chemical Space of Readily Accessible Screening Compounds , 2020, iScience.

[23]  V. Spiegelman,et al.  Targeting RNA-binding proteins in acute and chronic leukemia , 2020, Leukemia.

[24]  J. Karanicolas,et al.  Identification and Validation of an Aspergillus nidulans Secondary Metabolite Derivative as an Inhibitor of the Musashi-RNA Interaction , 2020, Cancers.

[25]  Xinbin Chen,et al.  Cancer The 'RBP'eutics - RNA-Binding Proteins as Therapeutic Targets for Cancer. , 2019, Pharmacology & therapeutics.

[26]  C. Crews,et al.  PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future. , 2019, Drug discovery today. Technologies.

[27]  A. Dömling,et al.  Novel Compounds Targeting the RNA-Binding Protein HuR. Structure-Based Design, Synthesis, and Interaction Studies. , 2019, ACS medicinal chemistry letters.

[28]  A. Quattrone,et al.  Screening Approaches for Targeting Ribonucleoprotein Complexes: A New Dimension for Drug Discovery , 2019, SLAS discovery : advancing life sciences R & D.

[29]  T. Chao,et al.  MSI1 associates glioblastoma radioresistance via homologous recombination repair, tumor invasion and cancer stem-like cell properties. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[30]  J. Karanicolas,et al.  Natural product derivative Gossypolone inhibits Musashi family of RNA-binding proteins , 2018, BMC Cancer.

[31]  J. Vogel,et al.  RNA-binding proteins in bacteria , 2018, Nature Reviews Microbiology.

[32]  Levi N. Naden,et al.  Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia , 2018, bioRxiv.

[33]  Sun Mi Park,et al.  Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells , 2017, Nature Genetics.

[34]  J. Karanicolas,et al.  Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic Targets , 2017, Clinical Cancer Research.

[35]  S. An,et al.  Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells. , 2016, International journal of oncology.

[36]  K. Mnich,et al.  Nerve growth factor (NGF)-mediated regulation of p75(NTR) expression contributes to chemotherapeutic resistance in triple negative breast cancer cells. , 2016, Biochemical and biophysical research communications.

[37]  L. Penalva,et al.  Musashi1 Impacts Radio-Resistance in Glioblastoma by Controlling DNA-Protein Kinase Catalytic Subunit. , 2016, The American journal of pathology.

[38]  D. Gibbons,et al.  Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis , 2016, Proceedings of the National Academy of Sciences.

[39]  A. Ben-Ze'ev Faculty Opinions recommendation of Expression of putative stem cell genes Musashi-1 and beta1-integrin in human colorectal adenomas and adenocarcinomas. , 2016 .

[40]  Shane T. Jensen,et al.  The Msi Family of RNA-Binding Proteins Function Redundantly as Intestinal Oncoproteins. , 2015, Cell reports.

[41]  Jeffrey D Levengood,et al.  The First Crystal Structure of the UP1 Domain of hnRNP A1 Bound to RNA Reveals a New Look for an Old RNA Binding Protein. , 2015, Journal of molecular biology.

[42]  S. Zhang,et al.  Musashi-2 Silencing Exerts Potent Activity against Acute Myeloid Leukemia and Enhances Chemosensitivity to Daunorubicin , 2015, PloS one.

[43]  R. Cohen,et al.  Natural product (−)‐gossypol inhibits colon cancer cell growth by targeting RNA‐binding protein Musashi‐1 , 2015, Molecular oncology.

[44]  Michael G. Kharas,et al.  Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. , 2015, The Journal of clinical investigation.

[45]  S. James,et al.  Current and future therapies for herpes simplex virus infections: mechanism of action and drug resistance. , 2014, Current opinion in virology.

[46]  Luis Menéndez-Arias,et al.  Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance. , 2014, Current opinion in virology.

[47]  J. Baell,et al.  Chemistry: Chemical con artists foil drug discovery , 2014, Nature.

[48]  P. Nordlund,et al.  The cellular thermal shift assay for evaluating drug target interactions in cells , 2014, Nature Protocols.

[49]  S. Butcher,et al.  Core structure of the U6 small nuclear ribonucleoprotein at 1.7-Å resolution , 2014, Nature Structural & Molecular Biology.

[50]  Eric J. Deeds,et al.  Structural Properties of Non-Traditional Drug Targets Present New Challenges for Virtual Screening , 2013, J. Chem. Inf. Model..

[51]  J. Eibl,et al.  Identification of novel pyrazoloquinazolinecarboxilate analogues to inhibit nerve growth factor in vitro. , 2013, European journal of pharmacology.

[52]  E. Arnold,et al.  HIV-1 reverse transcriptase and antiviral drug resistance. Part 2. , 2013, Current opinion in virology.

[53]  K. Neugebauer,et al.  How cells get the message: dynamic assembly and function of mRNA–protein complexes , 2013, Nature Reviews Genetics.

[54]  F. Allain,et al.  RRM-RNA recognition: NMR or crystallography…and new findings. , 2013, Current opinion in structural biology.

[55]  Anthony Nicholls,et al.  Conformer Generation with OMEGA: Learning from the Data Set and the Analysis of Failures , 2012, J. Chem. Inf. Model..

[56]  Gene W. Yeo,et al.  Genome-Wide Approaches to Dissect the Roles of RNA Binding Proteins in Translational Control: Implications for Neurological Diseases , 2012, Front. Neurosci..

[57]  Richard Bonneau,et al.  The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts. , 2012, Molecular cell.

[58]  Norman E. Davey,et al.  Insights into RNA Biology from an Atlas of Mammalian mRNA-Binding Proteins , 2012, Cell.

[59]  Ryan G. Coleman,et al.  ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..

[60]  V. Polunovsky,et al.  Attacking a Nexus of the Oncogenic Circuitry by Reversing Aberrant eIF4F-Mediated Translation , 2012, Molecular Cancer Therapeutics.

[61]  F. Massi,et al.  Allosteric inhibition of a stem cell RNA-binding protein by an intermediary metabolite , 2012, eLife.

[62]  S. Govoni,et al.  The complex world of post-transcriptional mechanisms: is their deregulation a common link for diseases? Focus on ELAV-like RNA-binding proteins , 2012, Cellular and Molecular Life Sciences.

[63]  David Ryan Koes,et al.  Small-molecule inhibitor starting points learned from protein–protein interaction inhibitor structure , 2011, Bioinform..

[64]  H. Okano,et al.  Structure of Musashi1 in a complex with target RNA: the role of aromatic stacking interactions , 2011, Nucleic acids research.

[65]  Eric B Fauman,et al.  Structure-based druggability assessment--identifying suitable targets for small molecule therapeutics. , 2011, Current opinion in chemical biology.

[66]  Ahmad M Khalil,et al.  RNA-protein interactions in human health and disease. , 2011, Seminars in cell & developmental biology.

[67]  H. Hellinga,et al.  Thermodynamic analysis of ligand-induced changes in protein thermal unfolding applied to high-throughput determination of ligand affinities with extrinsic fluorescent dyes. , 2010, Biochemistry.

[68]  Hideyuki Okano,et al.  Musashi1 regulates breast tumor cell proliferation and is a prognostic indicator of poor survival , 2010, Molecular Cancer.

[69]  Fatima Al-Shahrour,et al.  Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia , 2010, Nature Medicine.

[70]  Takahiro Ito,et al.  Regulation of myeloid leukemia by the cell fate determinant Musashi , 2010, Nature.

[71]  A. Marchand,et al.  Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. , 2010, Nature chemical biology.

[72]  Benjamin A. Ellingson,et al.  Conformer Generation with OMEGA: Algorithm and Validation Using High Quality Structures from the Protein Databank and Cambridge Structural Database , 2010, J. Chem. Inf. Model..

[73]  Sarath Chandra Janga,et al.  Dissecting the expression dynamics of RNA-binding proteins in posttranscriptional regulatory networks , 2009, Proceedings of the National Academy of Sciences.

[74]  W. Plunkett,et al.  Nucleoside analogs: molecular mechanisms signaling cell death , 2008, Oncogene.

[75]  Piotras Cimmperman,et al.  A quantitative model of thermal stabilization and destabilization of proteins by ligands. , 2008, Biophysical journal.

[76]  Cai-yun Zhou,et al.  Stem-cell-abundant proteins Nanog, Nucleostemin and Musashi1 are highly expressed in malignant cervical epithelial cells , 2008, BMC Cancer.

[77]  P. Tsonis,et al.  Molecular mimicry: structural camouflage of proteins and nucleic acids. , 2008, Biochimica et biophysica acta.

[78]  A. Baranger,et al.  Recognition of essential purines by the U1A protein , 2007, BMC Biochemistry.

[79]  Pedro A Fernandes,et al.  Hot spots—A review of the protein–protein interface determinant amino‐acid residues , 2007, Proteins.

[80]  A. Hackam,et al.  Human embryonic and neuronal stem cell markers in retinoblastoma , 2007, Molecular vision.

[81]  Christopher D. Thanos,et al.  Hot-spot mimicry of a cytokine receptor by a small molecule , 2006, Proceedings of the National Academy of Sciences.

[82]  Frédéric H.-T. Allain,et al.  Sequence-specific binding of single-stranded RNA: is there a code for recognition? , 2006, Nucleic acids research.

[83]  E. McLaughlin,et al.  The RNA-binding protein Musashi is required intrinsically to maintain stem cell identity. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[84]  C. Dominguez,et al.  The RNA recognition motif, a plastic RNA‐binding platform to regulate post‐transcriptional gene expression , 2005, The FEBS journal.

[85]  J. A. Grant,et al.  A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. , 2005, Journal of medicinal chemistry.

[86]  S. Vajda,et al.  Anchor residues in protein-protein interactions. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[87]  J. Rutka,et al.  Identification of differentially expressed and developmentally regulated genes in medulloblastoma using suppression subtraction hybridization , 2004, Oncogene.

[88]  A. Baranger,et al.  Substitution of an essential adenine in the U1A-RNA complex with a non-polar isostere. , 2002, Nucleic acids research.

[89]  R. Deshaies,et al.  Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[90]  H. Okano,et al.  Expression of the neural RNA‐binding protein Musashi1 in human gliomas , 2001, Glia.

[91]  K. Squires An Introduction to Nucleoside and Nucleotide Analogues , 2000, Antiviral therapy.

[92]  M Kjeldgaard,et al.  Macromolecular mimicry , 2000, The EMBO journal.

[93]  A. Baranger,et al.  Recognition of an Essential Adenine at a Protein−RNA Interface: Comparison of the Contributions of Hydrogen Bonds and a Stacking Interaction , 1999 .

[94]  T. Clackson,et al.  A hot spot of binding energy in a hormone-receptor interface , 1995, Science.

[95]  H. Okano,et al.  Musashi, a neural RNA-binding protein required for drosophila adult external sensory organ development , 1994, Neuron.

[96]  M. Gorospe,et al.  Identification of mRNA-Interacting Factors by MS2-TRAP (MS2-Tagged RNA Affinity Purification). , 2016, Methods in molecular biology.

[97]  Shenmin Zhang,et al.  Musashi2 modulates K562 leukemic cell proliferation and apoptosis involving the MAPK pathway. , 2014, Experimental cell research.

[98]  H. Field,et al.  Helicase-primase inhibitors for herpes simplex virus: looking to the future of non-nucleoside inhibitors for treating herpes virus infections. , 2014, Future medicinal chemistry.

[99]  E. McLaughlin,et al.  The Musashi family of RNA binding proteins: master regulators of multiple stem cell populations. , 2013, Advances in experimental medicine and biology.

[100]  E. Arnold,et al.  HIV-1 reverse transcriptase and antiviral drug resistance. Part 1. , 2013, Current opinion in virology.

[101]  Jens Meiler,et al.  ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. , 2011, Methods in enzymology.

[102]  T. Cihlar,et al.  Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. , 2010, Antiviral research.

[103]  W. Dong,et al.  Expression of putative stem cell genes Musashi-1 and β1-integrin in human colorectal adenomas and adenocarcinomas , 2009, International Journal of Colorectal Disease.

[104]  Shibo Jiang,et al.  HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. , 2007, Current pharmaceutical design.

[105]  H. Mehdorn,et al.  Expression of stem cell markers in human astrocytomas of different WHO grades , 2007, Journal of Neuro-Oncology.